HPV Testing as a Prevention of Cervical Dysplasia and Cancer Before Planned Subtotal Hysterectomy

N/ANot Yet RecruitingNCT07545525

General University Hospital, Prague300 enrolled

Overview

Patients indicated for subtotal hysterectomy will be tested for High risk HPV and if the result is positive will undergo expert colposcopy and conisation if not indicated otherwise at the time of subtotal hysterectomy

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Cervical Cancer Screening Human Papilloma Virus (HPV)

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age over 18 * indication for subtotal hysterectomy * consent to provide conisation in case the HPV test result is positive Exclusion Criteria: * negative HPV test in the last 3 years

Outcomes

Primary Outcomes

Benefit of addition of HPV DNA testing before subtotal hysterectomy

Prevalence of HPV positivity in the tested cohort (patients indicated for subtotal hysterectomy). Prevalence of HPV (other than HPV 16 and 18) positivity in the tested cohort (patients indicated for subtotal hysterectomy). Prevalence of abnormal oncological cytology result and correlation to HPV result in the tested cohort (patients indicated for subtotal hysterectomy). Prevalence of cervical intraepithelial leasions in patients who underwent cone biopsy with the subtotal hysterectomy. Prevalence of high grade cervical intraepithelial leasions in patients who underwent cone biopsy with the subtotal hysterectomy. Rate of HPV negativity 6 months after cone biopsy.

Time frame: 3 years

Central Contacts

Tomas Fučík, M.D.

CONTACT

724188696 fuciktomas93@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.